Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: To lump or split?

BMC Pulmonary Medicine

Volumn 15, Issue 1, 2015, Pages

  Ikeda, Satoshi ^a   Arita, Machiko ^a   Morita, Mitsunori ^a   Ikeo, Satoshi ^a   Ito, Akihiro ^a   Tokioka, Fumiaki ^a   Noyama, Maki ^a   Misaki, Kenta ^a   Notohara, Kenji ^a   Ishida, Tadashi ^a  

^a KURASHIKI CENTRAL HOSPITAL   (Japan)

Author keywords

Amyopathic dermatomyositis; Interstitial lung diseases; MDA 5 protein, human; Melanoma differentiation associated protein 5, human

Indexed keywords

ANTIBODY; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GAMMA GLUTAMYLTRANSFERASE; MELANOMA DIFFERENTIATION ASSOCIATED GENE 5 ANTIBODY; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; DEAD BOX PROTEIN; IFIH1 PROTEIN, HUMAN;

ADULT; ARTICLE; CD4 CD8 RATIO; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICALLY AMYOPATHIC DERMATOMYOSITIS; CONTROLLED STUDY; DERMATOMYOSITIS; FATALITY; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMAGE ANALYSIS; INTERSTITIAL LUNG DISEASE; LUNG LAVAGE; MALE; MEDICAL RECORD REVIEW; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; AGED; BLOOD; COMPLICATION; DISEASE COURSE; IMMUNOLOGY; LUNG DISEASES, INTERSTITIAL; LUNG FUNCTION TEST; MIDDLE AGED; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; AGED; ANTIBODIES; BIOMARKERS; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DEAD-BOX RNA HELICASES; DERMATOMYOSITIS; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PROGNOSIS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84952877276     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-015-0154-4     Document Type: Article

References (31)

1. Sontheimer RD, Miyagawa S. Potentially fatal interstitial lung disease can occur in clinically amyopathic dermatomyositis. J Am Acad Dermatol. 2003;48:797-8.
2. High WA, Cohen JB, Murphy BA, Costner MI. Fatal interstitial pulmonary fibrosis in anti-Jo-1-negative amyopathic dermatomyositis. J Am Acad Dermatol. 2003;49:295-8.
3. Ye S, Chen XX, Lu XY, Wu MF, Deng Y, Huang WQ, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol. 2007;26:1647-54.
4. Sun Y, Liu Y, Yan B, Shi G. Interstitial lung disease in clinically amyopathic dermatomyositis (CADM) patients: a retrospective study of 41 Chinese Han patients. Rheumatol Int. 2013;33:1295-302.
5. Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest. 2009;136:1341-7.
6. Nawata Y, Kurasawa K, Takabayashi K, Miike S, Watanabe N, Hiraguri M, et al. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. J Rheumatol. 1999;26:1527-33.
7. Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K, Matsuoka S, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford). 2007;46:124-30.
8. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60:2193.
9. Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010;49:433.
10. Chen Z, Cao M, Plana MN, Liang J, Cai H, Kuwana M, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis. Care. Res (Hoboken). 2013;65:1316-24.
11. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46:626-36.
12. Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54:597-613.
13. Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, Cadranel J, Delaval P, Ternamian PJ, et al. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J. 2003;22:245-50.
14. Kubo M, Ihn H, Yamane K, Kikuchi K, Yazawa N, Soma Y, et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology (Oxford). 2000;39:632-6.
15. Fathi M, Barbasso Helmers S, Lundberg IE. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med. 2012;271:589-97.
16. Ihn H, Asano Y, Kubo M, Yamane K, Jinnin M, Yazawa N, et al. Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease. Rheumatology (Oxford). 2002;41:1268-72.
17. Otsuka M, Takahashi H, Fujisima T, Nishiyama K, Kon H, Outi H, et al. New serum markers to monitor treatment of acute exacerbation of interstitial lung disease. Nihon Kokyuki Gakkai Zasshi. 2001;39:298-302.
18. Sakamoto K, Taniguchi H, Kondoh Y, Johkoh T, Sumikawa H, Kimura T, et al. Serum KL-6 in fibrotic NSIP: Correlations with physiologic and radiologic parameters. Respir Med. 2010;104:127-33.
19. Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y, et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med. 2000;162:1109-14.
20. Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford). 2012;51:1278-84.
21. Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49:1713-9.
22. Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med. 2011;105:1380-7.
23. Suda T, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Naito T, et al. Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J. 2006;28:1005-12.
24. Ito M, Kaise S, Suzuki S, Kazuta Y, Sato Y, Miyata M, et al. Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol. 1999;18:462-7.
25. Lee CS, Chen TL, Tzen CY, Lin FJ, Peng MJ, Wu CL, et al. Idiopathic inflammatory myopathy with diffuse alveolar damage. Clin Rheumatol. 2002;21:391-6.
26. Sakurai N, Nagai K, Tsutsumi H, Ichimiya S. Anti-CADM-140 antibody juvenile dermatomyositis with rapidly progressive interstitial lung disease and cardiac involvement. J Rheumatol. 2011;38:963-4.
27. Morita Y, Kuwagata S, Kato N, Tsujimura Y, Mizutani H, Suehiro M, et al. 18F-FDG PET/CT useful for the early detection of rapidly progressive fatal interstitial lung disease in dermatomyositis. Intern Med. 2012;51:1613-8.
28. Miyake M, Sakai A, Nishijima C, Kita T, Nitta E, Kawashima A, et al. Detection of anti-CADM-140/MDA5 antibodies in a patient with classic dermatomyositis developing rapidly progressive interstitial lung disease. J Dermatol. 2014;41:664-5.
29. Miyazaki E, Ando M, Muramatsu T, Fukami T, Matsuno O, Nureki S, et al. Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis. Clin Rheumatol. 2007;26:436-9.
30. Chow SK, Yeap SS. Amyopathic dermatomyositis and pulmonary fibrosis. Clin Rheumatol. 2000;19:484-5.
31. Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford). 2010;49:1726-33.